Delcath Systems (NASDAQ:DCTH) Given Overweight Rating at Stephens

Delcath Systems (NASDAQ:DCTH - Get Free Report)'s stock had its "overweight" rating reaffirmed by stock analysts at Stephens in a research note issued to investors on Monday,Benzinga reports. They presently have a $25.00 price target on the stock. Stephens' target price points to a potential upside of 85.51% from the company's current price.

A number of other research firms have also recently issued reports on DCTH. HC Wainwright reiterated a "buy" rating and issued a $29.00 target price (up from $24.00) on shares of Delcath Systems in a research note on Friday, May 23rd. Wall Street Zen lowered shares of Delcath Systems from a "strong-buy" rating to a "buy" rating in a research note on Sunday, June 1st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $24.00.

Delcath Systems Stock Performance

Shares of NASDAQ DCTH traded down $0.37 during trading on Monday, reaching $13.48. The stock had a trading volume of 120,003 shares, compared to its average volume of 389,519. The stock has a market cap of $469.37 million, a PE ratio of -27.01 and a beta of 0.94. Delcath Systems has a one year low of $7.17 and a one year high of $18.23. The firm's 50 day moving average price is $14.43 and its two-hundred day moving average price is $13.72.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.07). Delcath Systems had a negative net margin of 26.38% and a negative return on equity of 29.44%. The business had revenue of $19.80 million for the quarter, compared to the consensus estimate of $16.83 million. On average, research analysts expect that Delcath Systems will post -0.79 earnings per share for the current year.

Institutional Trading of Delcath Systems

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. grew its stake in shares of Delcath Systems by 28.8% in the 4th quarter. Principal Financial Group Inc. now owns 115,183 shares of the company's stock worth $1,387,000 after purchasing an additional 25,736 shares during the last quarter. Private Advisor Group LLC purchased a new stake in Delcath Systems in the 4th quarter worth approximately $153,000. Charles Schwab Investment Management Inc. acquired a new stake in Delcath Systems during the fourth quarter valued at $156,000. Quantbot Technologies LP acquired a new position in Delcath Systems in the fourth quarter worth approximately $66,000. Finally, Simplify Asset Management Inc. acquired a new position in shares of Delcath Systems during the 4th quarter worth $205,000. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.